Merck’s Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

 Merck’s Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

Merck’s Keytruda (pembrolizumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma (HCC)

Shots:

  • The KEYNOTE-224 study involves assessing of Keytruda (200mg q3w @24mos) in 104 patients with HCC aged ≥65, previously treated or intolerant to sorafenib
  • KEYNOTE-224 study results: ECOG PS 0 or 1 (61% or 39%); Child Pugh class A5/A6/B7/B8 (72%/22%/5%/1%); HBV & HCV seropositive (21% & 25%); ORR (17%); CR (1%); PR (16%); mDOR @ 6mos.&12mos. (89% & 56%)
  • Keytruda is a mAb, works as an anti-PD -1 therapy for tumor cells and has received 14 approvals including one for HCC & is evaluated in > 850 trials in for different cancers

Click here to read full press release/ article | Ref: Merck | Image: Chemistry World

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post